NOVAVAX COVID-19 Vaccine Candidate Completes Phase 3 Enrollment Requirements
As Pfizer and Moderna vaccines make their way across the United States, a new candidate is one step closer to emergency use authorization.
Biotechnology company Novavax announced the completion of enrollment for their NVX-CoV2373 vaccine. On February 22nd the company announced completion of enrollment for their phase 3 trials in the U.S. and Mexico.
The company has met the goal of 30,000 of its two dose protein based vaccine candidates. That vaccine is said to be administered to individuals 18 and older 21 days apart. .
Continuing in phase 3 trials means their one step closer towards approval and distribution in the upcoming weeks.
Meanwhile, another vaccine candidate from pharmaceutical Johnson & Johnson is expecting emergency approval as early as the end of the week.